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It is well established that people with diabetes mellitus have a
greater risk of cardiovascular morbidity and mortality than their
normal counterparts [1]. More than 50% of diabetes-related deaths are
associated with macrovascular complications, especially atheroscle-
rosis [2]. Multiple risk factors are associated with atherosclerosis,
including hyperglycemia, hyperlipidemia, and dysregulation of the
angiotensin system [3,4].
Recent studies show that oxidative stress and advanced glycation
also play an important role in the development of diabetic macro-
vascular disease [5,6]. AGE contributes to the progression of
atherosclerosis and accelerates oxidative stress by interacting with a
speciﬁc receptor RAGE on vascular cells [7–10].
RAGE, a member of the immunoglobulin superfamily of cell surface
molecules, is a multi-ligand receptor on vascular cells that plays a key
role in inﬂammatory processes [11]. Unlike other receptors that aredownregulated by increased levels of their ligands, the RAGE-ligand
interaction leads topositive feedback activation,which further increases
receptor expression [12]. There is increasing evidence that in diabetic
patients, activation of the AGE-RAGE pathway plays a central role in the
cascade of events that result in accelerated atherosclerotic plaque
formation, plaque erosion and ﬁssuring [13,14].
In addition to AGE, other cytokines and proinﬂammatory molecules
can also upregulate RAGE expression [15,16]. For example, MCP-1, a
downstream target of the AGE-RAGE signal pathway [17–19], is one of
these ligands, thus constituting a positive feedback cascade.MCP-1 is an
essential chemokine responsible for the recruitment and activation of
monocytes to inﬂammatory lesions in the vasculature, an initial step in
the progression towards atherosclerosis [17,20].
Recent clinical trials have shown that statins, the competitive
inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, reduce cardiovascular events and mortality in diabetics
[21,22]. In animal models, statins exert a beneﬁcial effect on aortic
plaque composition, resulting in a decrease in the proportion of
advancedplaques and an increase in plaque stability [23,24]. In addition,
statins have many other effects, including anti-inﬂammation, anti-
oxidative stress, and improving endothelial function [25,26]. These
cholesterol-independent effects have been suggested to attenuatemany
of the stAGE critical to atherosclerosis (see reviews [27–30]). However,
the speciﬁc mechanism of statins on atherosclerosis is still unknown.
We proposed to examine whether atorvastatin exerts part of its
inhibitory role on the progression of atherosclerosis by targeting
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expression of RAGE and its downstream target gene in HUVECs and in
Goto Kakisaki (GK) rats. The GK rat was used as a non-obese model of
type 2 diabetes. It has been reported that in this model, high-fat
feeding markedly impairs glucose-induced insulin secretion in islets
[31] and results in a type 2 diabetes phenotype characterized by an
increase in fasting hyperglycaemia, plasma triglycerides and choles-
terol, impaired early-phase insulin secretion in response to food
intake, hepatic insulin resistance, and abnormal glucose metabolism
[32–34]. We were particularly interested in whether in this model,
statins alter the AGE-RAGE interaction and suppress their potential
target gene RAGE expression in the early stAGE of atherosclerosis,
especially in the atherosclerotic aortas far before obvious plaques can
be detected.
2. Materials and methods
2.1. Cell culture
RPMI-1640 nutrient medium and fetal bovine serum were
purchased from Invitrogen (Carlsbad, CA); VEGF was supplied by
Upstate Biotechnology (Lake Placid, NY); Trizol reagent was provided
by Invitrogen (Carlsbad, CA); type I collagenase (100 mg) was from
Sigma (St. Louis, MO); and the atorvastatin was provided by Honghui
pharmaceuticals (Peking, China).
Human umbilical vein endothelial cells (HUVECs) were cultured in
our lab and HUVECs at passage 3–4 were used for experiments, and
the cells were cultured with serum-free RPMI-1640 medium for 24 h
before treatment. The HUVECs were randomly assigned to 6 groups
as follows: (1) high glucose (30 mmol/L); (2) high AGE (400 μg/ml);
(3) high glucose (30 mmol/L) plus atorvastatin (12 mg/L); (4) high
AGE (400 μg/ml) with atorvastatin (12 mg/L); (5) control group and
(6) high mannitol (30 mmol/L). Cells were cultured at 37 C for 24 h
with 5% CO2. After 24 h, the cells were observed and photographed.
The culture supernatants of treatment groups were collected for the
measurement of glutathione (GSH) and malondialdehyde (MDA),
which were used as the anti-oxidative and the oxidative index,
respectively.
2.2. Preparation of advanced glycation end products-human serum
albumin (AGE-HAS)
Human serum albumin (HSA) and D-glucose were dissolved in
PBS (pH 7.2–7.4), and the ﬁnal concentrations of HSA and D-glucose
was 5 g/L and 50 mmol/L, respectively. EDTA was added to a ﬁnal
concentration of 0.5 mmol/L to reduce oxidation. Penicillin (100 U/L)
and streptomycin (100 μg/ml) were added to the reaction mixture to
prevent bacterial contamination. The reaction mixture was ﬁltered
through 0.22 μm ﬁlter and then incubated in electrothermal incuba-
tion at 37 °C for 12 weeks. At the end of the incubation period, the
reaction mixture was dialyzed against sterilized PBS (pH 7.2–7.4) to
remove the unconjugated glucose; the glucose in the dialyzate was
b0.03 mmol/L. The reaction mixture was measured in a ﬂuorospec-
trophotometer with an excitation wave of 370 nm, and the maximum
absorption peak was measured at 440 nm to verify that the mixture
was AGE-HSA. Finally, the AGE-HSA was freeze-dried and stored at
4 °C.
2.3. Animals and diets
Nine male Goto Kakisaki (GK) rats (Scientiﬁc research institute,
Shanghai, China), weighing approximately 380 g, were randomly
divided into two groups: diabetic control group (ﬁve rats) and
atorvastatin-treated diabetic group (four rats). Five male Wistar rats
(Scientiﬁc research institute, Shanghai, China), weighing approxi-
mately 350 g–370 g, were included as the normal control group. Ratsin the atorvastatin-treated group were treated with atorvastatin
(Lipitor, Pﬁzer Ireland Pharmaceuticals), 20 mg/kg/day, through
intragastric administration. All rats were fed for 12 weeks with
high-fat diet, consisting of 78.5% normal diet, 1% cholesterol, 0.5% bile
salt, and 20% lard. All rats were given vitamin D3 (6×105 IU/kg)
through intragastric administration from the ﬁrst day to the third day
to accelerate atherosclerosis formation. Body weight was measured
weekly. Blood samples were drawn from the caudal vein every two
weeks until the end of the experiment. Fasting blood glucose levels
were measured by glucose oxidase-peroxidase (GOD-POD) kit
(Sigma, MO). All animal experiments were conducted according to
the protocol approved by the Animal Committee of Animal Center of
East Hospital, Tongji University.2.4. Tissue collection
Rats were sacriﬁced at the end of 12 weeks and the chest was
opened by midline incision. The aortas were rapidly removed and
rinsed with ice-cold saline. For each aorta sample, about 1 mm3 was
stored in 2.5% glutaral for analysis by transmission electron
microscope (TEM). The remaining portions of aorta were frozen by
dipping in liquid nitrogen, and then stored at −80 °C.2.5. mRNA quantitation by real-time PCR
Total RNAwas isolatedwith the trizol method and depuratedwith a
RNAeasy kit (Invitrogen, CA). RNA was stored at −80 °C until reverse
transcription was performed. An aliquot (1 μg) of extracted RNA was
reverse-transcribed into theﬁrst strand of complementary DNA (cDNA)
at 42 °C for 40 min, using 100 U/ml reverse-transcriptase (Takara
Biochemicals, Shiga, Japan) and 0.1 μM of oligo (dt)-adapter primer
(Takara) in a 50ul reaction mixture. Real-time polymerase chain
reaction (PCR) was carried out with an ABI Prism 7000 Real-Time PCR
system, using the DNA-binding dye SYBER Green I for the detection of
PCR products. The reaction mixture (RT-PCR kit, Takara) contained
12.5 μl Premix Ex Tag, 2.5 μl SYBER Green I, custom-synthesized
primers, ROX reference dye, cDNA (equivalent to 20 ng total RNA)
to give a ﬁnal reaction volume of 25 μl. Primers were as follows: β-
actin: sense 5′ TCTGTGTGGATTGGTGGCTCT 3′, antisense 5′ AGAAG-
CATTTGCGGTGCAC 3′; RAGE: sense 5′CCTGTGGCGAAAACGACAA3′,
antisense 5′TCTGGCATTTCCGCTTCCT3′; MCP-1: sense 5′CAGATGCAGT-
TAATGCCCCA3′, antisense 5′CCTGCTGCTGGTGATTCTCTT3′. The PCR
settings were as follows: initial denaturation of 15 min at 70 °C,
followed by 40 cycle of ampliﬁcation for 15 s at 95 °C and 1 min at
59 °C, with subsequent melting curve analysis increasing the temper-
ature from 60 to 95 °C. In order to quantify RAGE and MCP-1 gene
expression, the RAGE and MCP-1 mRNA level was normalized by
internal β-actin mRNA.2.6. Transmission electron microscopy (TEM) test
After ﬁxation in glutaral, aortas were put into 1% osmic acid,
dehydrated with acetone, embeddedwith Epon812, sliced with LKB-V
microtome, double stained with lead and uranium, and observed
under an H-600A transmission electron microscope.2.7. Data analysis
All data were expressed as mean±SD. Kruskal–Wallis one-way
analysis of variance was used to assess the differences between inner-
groups and inter-groups using SPSS 11.5 software. Values of Pb0.05
were considered to be statistically signiﬁcant.
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Fig. 1. Cell growth andmorphologic changes of HUVEC treatedwith high glucose and AGE. HUVE cells were treated for 24 hwith A: PBS control; B: highmannitol control (30 mmol/L); C: high
glucose (30mmol/L); D: high glucose+atorvastatin (12 mg/L); E: high AGE (400 μg/ml); F: high AGEwith atorvastatin (12 mg/L); G: Cell death in each treatment group (quantitated as dead
cells/microscopic ﬁeld). Data are expressed asmean±SD in each group. * comparedwith the control group, Pb0.05; ** comparedwith the high glucose group, Pb0.05; *** comparedwith the
AGE group, P=0.5. Photos were taken 24 h after treatment. (Dead cells are shown in yellow).
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3.1. Atorvastatin-mediated reduction of abnormal HUVEC growth from
high glucose and AGE
Vascular disease caused by diabetes mellitus is related to high
serum glucose and AGE levels. In the in vitro model, we incubated
HUVECs with high glucose and AGE (Fig. 1). Exposure to high glucose
and AGE resulted in a reduction in cell growth, primarily due to
prominent cell death (Figs. 1C, E). However, treatment with
atorvastatin reduced cell death caused by high glucose (Fig. 1D) and
AGE (Fig. 1F). As the treatment control, highmannitol did not alter cell
morphology and cell growth (Fig. 1B), indicating that hyperosmosis
has no signiﬁcant impact on the HUVECs. For comparison, cell death in
each treatment group was quantitated and summarized in Fig. 1G.
3.2. Biochemical measurement of oxidative stress
AGE accelerates oxidative stress by interacting with a speciﬁc
receptor RAGE on vascular cells. To determine the involvement of
oxidative stress in cell death of HUVECs, we measured GSH (indicator
of redox status) and MDA (indicator of lipid peroxidation induced by
oxygen free radicals) in cell supernatants (Fig. 2). The mannitol
treatment did not alter GSH levels as compared with the control
group. However, there was signiﬁcant decrement in GSH afterG
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Fig. 2. Measurement of oxidative indicators GSH (A) and MDA (B) in the collected
supernatants of treated HUVEC. Data are expressed as mean±SD in each group.
* compared with the control group, Pb0.01; ** compared with the high glucose group,
Pb0.01; *** compared with the AGE group, Pb0.05.exposure of the cells to high glucose or AGE, indicating an increased
oxidative stress of the treated cells. Treatment of the cells with
atorvastatin signiﬁcantly released the oxidative stress by restoring the
levels of GSH (Fig. 2A) (Pb0.01).
Similarly, incubation of cells with high glucose and AGE caused a
dramatic increase in MDA production. Atorvastatin suppressed the
production of lipid peroxidation from oxygen free radicals following
the treatment of high glucose and AGE (Fig. 2B) (Pb0.01).
3.3. Atorvastatin targets RAGE expression in HUVECs
To further explore the role of atorvastatin in protecting HUVECs
from cell death, we measured the expression of its target genes. We
initially focused on the RAGE gene. After incubation with high glucose
and AGE, HUVECswere collected and used for quantitation of RAGE by
real-time PCR. As seen in Fig. 3, both high glucose and AGE-induced
upregulation of RAGE mRNA in HUVECs. However, treatment of cells
with atorvastatin led to the downregulation of RAGE to the basal level
seen in both PBS and mannitol control cells.
3.4. Downregulation of RAGE and its downstream target MCP-1 by
atorvastatin in GK rats
Given the beneﬁcial effect of atorvastatin in HUVECs, we further
examined its therapeutic effect in adiabeticGKratmodel. Afterbeing feda
high-fat diet for 12 weeks, blood glucose levels were signiﬁcantly
increased in diabetic group (n=5, 12.7 mmol/L±4.2 mmol/L) as
compared with that in the normal control group (n=5, 5.9±
0.2 mmol/L) (Pb0.01) (Fig. S1). No signiﬁcant effect on plasma glucose
was observed in atorvastatin-treated diabetic group.
To further examine the role of atorvastatin in this GK ratmodel, we
used RT-PCR to quantitate the expression of RAGE in the aorta. As
compared with the normal control group, expression of RAGE mRNA
was signiﬁcantly increased in the diabetic control group (Fig. 4A)
(Pb0.01). In the atorvastatin-treated diabetic group, however, RAGE
mRNA levels were signiﬁcantly downregulated to a level comparable
to those observed in the normal control group.
In addition to AGE, there is a potential link between inﬂammation
and insulin resistance in obese mice. Thus, we measured the
expression of MCP-1, which is a downstream target of the AGE-
RAGE pathway, and also plays an important role in the recruitment
and activation of monocytes in rat aorta. In this study, we observed a
signiﬁcant correlation between the abundance of RAGE mRNA and0.0
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Fig. 3. Expression of the receptor for the advanced glycation end products (RAGE) in
HUVEC received varied treatments. The abundance of RAGE mRNA was measured by
real-time qPCR, standardized over internal control β-actin mRNA, and expressed using
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Fig. 4. Atorvastatin downregulated RAGE (A) and MCP-1 (B) in diabetic GK rats.
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between these two molecules in the ampliﬁcation of inﬂammatory
responses. As seen in Fig. 4B, MCP-1 was signiﬁcantly upregulated in
the aorta of the diabeticmice. Treatment of atorvastatin reducedMCP-
1 production, supporting a second pathway by which the statin
protects mice from high-fat diet-induced diabetes.3.5. Morphologic changes of TEM
We also used transmission electron microscopy (TEM) to examine
structural alteration in the aortas of GK rats fed a high-fat diet. Early
pathological changes of atherosclerosis were observed in the aortas of
diabetic rats (Fig. 5), such as proliferation of smooth muscle cells
(SMC), lipid droplet in the cytoplasm of SMC, proliferation of ﬁber
between SMC, lipid droplet in the basal membrane of aortas,
endometrial thickening. No signiﬁcant improvement in the patholog-
ical changes was noticed by atorvastatin treatment in this model.4. Discussion
As an inhibitor of HMG-CoA reductase, atorvastatin is used
extensively to lower serum cholesterol levels. Reduction of total and
low-density lipoprotein cholesterol by atorvastatin has been shown to
translate into the reduced risk of long-term morbidity and mortality
related to coronary artery disease (see reviews [35–37]). Depending
on the model used, animals fed a high-fat diet usually develop
hyperlipidemia. Atorvastatin therapy is very effective in lowering
serum lipid levels in these animals, including cholesterol and
triglyceride [38–41]. For example, Hamed et al. [42] reported that
male Sprague–Dawley rats fed a high cholesterol diet for 8 weeks
increased serum cholesterol by 257% (pb0.001) as compared to the
control group fed standard diet. Low dose of atorvastatin induced
reduction in cholesterol level by 40% (Pb0.001). Combined treatment
of atorvastatin with other reagents, like garlic extracts, induced even
more pronounced hypolipidemic effect.
The efﬁcacy of statin therapy for reducing mortality and morbidity
of cardiovascular disease (CVD) in patients with diabetes is now well
established. However, statins may be able to reduce cardiovascular
events by mechanisms other than its ability to lower the level of
serum lipids, i.e. the “pleiotropic” actions [43,44]. This concept has
been further proven by experimental and clinical studies that have
shown that statins exhibit a variety of nonlipid effects, including
immuno-modulation, anti-proliferation, and anti-thrombosis, im-
provement of endothelial dysfunction, increased nitric oxide bioavail-
ability, antioxidant properties, inhibition of inﬂammatory responses,
and stabilization of atherosclerotic plaques (See reviews [45–47]).
RAGE activation is known to be associated with activation of the NF-
kappaB pathway. The RAGE gene promoter contains three putative
NF-kappaB-like binding sites that respond to the inﬂammatory
stimuli [48]. On the other hand, the activation of the AGE/RAGE also
results in generation of intracellular oxidative stress and subsequent
activation of the redox-sensitive transcription factor NF-kappaB
[49,50]. The activation of the NF-kappaB pathway by RAGE may
further amplify RAGE expression in inﬂammatory cells, constituting a
positive control cascade between oxidant stress and the altered AGE-
RAGE system. It has been suggested that statins may reduce AGE
accumulation and reduce activation of NADPH oxidase [10]. We also
found that atorvastatin treatment improved the oxidative stress index
and attenuated inﬂammation, and reduced cell death of human
umbilical vein endothelial cells following exposure to advanced
glycation end products. The data in this study, however, suggest
that atorvastatin exerts its therapeutic role at least in part by targeting
the RAGE activation.
Using the high-fat feeding GK rats as a model, we also show that
atorvastatin downregulates RAGE in the very early stAGE of
atherosclerosis, before its therapeutic improvement of the athero-
sclerotic lesions can be detected histologically. Interestingly, we also
found that this gene downregulation on the AGE-RAGE system was
not accompanied by the altered serum glucose (Fig. S1), indicating a
glucose-independent mechanism. Thus, our data demonstrate that
downregulation of the RAGE gene may be a novel “pleiotropic”
mechanism of atorvastatin in reducing the risk of cardiovascular
diseases.
However, it is still unclear how atorvastatin modiﬁes the
expression of genes involved in the RAGE pathway. Does atorvastatin
down-regulate the RAGE gene directly by binding and interfering with
its promoter activity, or indirectly by modifying the epigenotype
around the RAGE gene promoter, like DNA methylation and/or
histone acetylation and methylation? Atorvastatin has been reported
to affect expression of many other genes involved in pathogenesis of
cardiovascular diseases, like peroxisome proliferator activated recep-
tor-γ (PPAR-γ) [51], lysyl oxidase [52], monocyte chemoattractant
protein-1 (MCP-1) [53,54], interleukin-8 (IL-8) [54], plasminogen
activator inhibitor-1 (PAI-1) [55], and nitric oxide synthase (iNOS)
Fig. 5. Morphological changes of aortas as observed by transmission electron microscopy (TEM). A: Proliferation of smooth muscle cells (SMC) in aortas of diabetic rats (×6000);
B: Lipid droplet in the cytoplasm of SMC in aortas of diabetic rats (×8200); C: proliferation of ﬁber between SMC in aortas of diabetic rats (×8200); D: lipid droplet in the basal
membrane of aortas of diabetic rats (×6000); E: SMC in aortas of normal control group (×8200); F: Endothelial Cells in aortas of normal control group (×4200).
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gene expression proﬁle (165 elevated and 281 suppressed genes)
induced by the atherogenic diet [57]. Thus, it is highly possible that
atorvastatin modiﬁes an array of genes through an epigenetic
mechanism. Further studies are merited to examine the mechanism
underlying gene regulation using epigenetic techniques, like DNA
methylation sodium bisulﬁte sequencing and chromatin immunopre-
cipitation (ChIP).
AGE-RAGE interaction can be blocked by truncated soluble isoforms
of the receptor, referred to as total soluble RAGE (sRAGE), derived from
either the products of endogenous splice variants (endogenous
secretary receptor or esRAGE) [58,59], or the proteolytically cleaved
forms shed into the bloodstream upon digestion of extracellular
metalloproteinases [60]. These truncated sRAGE can modulate AGE-
mediated pathogenesis and immune modulation, probably by acting as
an endogenous decoy protecting factor to exert their anti-atherogenic
effects [61]. Indeed, hypercholesterolemic subjects have signiﬁcantly
lower circulating sRAGE levels than age-matched control subjects.
Interestingly, treatment of atorvastatin restores the sRAGE levels near to
normal values [62]. Tam et al. [63] demonstrated that atorvastatinincreased serum sRAGE and esRAGE in type II diabetic patients by
inducing their production in macrophAGE in a time- and dose-
dependent manner. However, it remains to be investigated whether
atorvastatin increases sRAGE production at the post-transcription level
or at the level of gene transcription as in the case of RAGE observed in
this study.
Most previous studies have primarily focused on the effect of
atorvastatin on RAGE expression in atherosclerotic plaque and on the
plaque's instability [64,65]. In our study, higher expression of RAGEwas
found in aortas of diabetic group rats compared with normal control
group even in the very early stage of atherosclerosis. Our study
demonstrates that diabetic animals demonstrated a signiﬁcant incre-
ment in RAGE expression even before obvious plagues were detected in
the aortas. Still, RAGE expression inGK ratswas signiﬁcantly reduced by
atorvastatin independent of glycemic control. Early expression of RAGE
could be caused by the high expression of the main ligands such as
inﬂammatory factors in diabetic aortas. However, the reduction of RAGE
byatorvastatin hasnot fully translated into a signiﬁcant improvement in
early pathological changes. Further studies are needed to examine the
long-term effects of down-regulating AGE/RAGE in this rat model.
1136 B. Feng et al. / Biochimica et Biophysica Acta 1812 (2011) 1130–1137Clinical evidence has shown that atorvastatin therapy reduces the
risk of cardiovascular disease by decreasing serum total cholesterol
and low-density lipoprotein cholesterol [35–37]. However, due to the
limit of blood samples collected from the caudal vein, we could not
determine serum cholesterol and triglyceride in our GK rats fed a
high-fat diet. As a result, we were unable to evaluate the lipid-
lowering effect of atorvastatin in the present study that focuses on the
RAGE pathway. This limitation will be addressed in our future studies.
There is a growing body of evidence that engagement of RAGE
with AGE elicits oxidative stress generation and subsequently evokes
inﬂammatory responses in various types of cells, thus actively
participating in the development and progression of atherosclerosis
[66,67]. Therefore, RAGE may play a pro-atherogenic role in diabetic
arteries. Okamoto et al. reported that Cerivastatin completely
prevented the AGE-induced increase angiogenesis by inhibiting the
AGE-induced transcriptional activation in NFKB signaling pathways
[68]. Jinnouchi et al. for the ﬁrst time demonstrated that atorvastatin
decreased serum levels of AGE in hypercholesterolaemic type 2
diabetic patients without any cardiovascular disease [69]. In this
study, we also demonstrated that atorvastatin suppressed the AGE/
RAGE pathway by a gene targeting mechanism. Thus, downregulation
of RAGE expression or blockade of RAGE downstream signaling may
be a promising target for therapeutic intervention in diabetic
atherosclerosis.
In addition to AGE, many RAGE downstream molecules, like
cytokines and proinﬂammatory products, also upregulate RAGE
expression [15,16], thus forming a positive feedback cascade. For
example, MCP-1 is an AGE-RAGE downstream target. It also acts as
one of the important ligands for RAGE and stimulates its expression. In
this study, we found that MCP-1 is downregulated in HUVECs by the
atorvastatin treatment. Thus, atorvastatin may reduce the activation
of the AGE/RAGE pathway partially by breaking the feedback of
inﬂammatory factor MCP-1. Thus, atorvastatin may beneﬁt diabetic
patients by blocking the AGE-RAGE signal pathway at multiple levels.
RAGE downregulation in diabetic aortas treatedwith atorvastatinmay
establish a negative auto-inhibitory autocrine and paracrine feedback
loop, thus delaying the formation and development of atherosclerosis.
In conclusion, this study proposes an etiologic hypothesis regarding
statin therapy and atherogenesis in diabetics by demonstrating the
inhibition of the functional AGE/RAGE axis after atorvastatin therapy.
These ﬁndings are also potentially important from a practical
standpoint, because they raise the interesting possibility that modiﬁ-
cation of RAGE signaling by statins might provide a novel form of
therapy for preventing formation and development of atherosclerosis in
diabetic patients.
Supplementarymaterials related to this article can be found online
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